Study of effectiveness of the switch from Gn-RH agonist to degarelix for patients with prostate cancer as a second-line hormone therapy
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2018
Price : $35 *
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms FELIX
- 12 Aug 2018 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Results (n=37) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 13 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.